Experts identify clinical standards for adverse effects to TB treatment
A panel of 65 global experts have identified eight clinical standards for the management of adverse effects during treatment for tuberculosis (TB).
Assessing TB-related comorbidities, risks and disability in China
A new study in China has found that it was possible and valuable to assess people with tuberculosis (TB) for symptoms, comorbidities, risk factors and disability at the start and end of TB treatment.
Risk of TB nine times higher in prisons globally
For the first time ever researchers, sponsored by The Union, have estimated the rate of tuberculosis (TB) in incarcerated persons, having analysed data from almost every country in the world (193 out of 195 countries) between 2000 and 2019.
Challenges of ending drug-resistant tuberculosis (DRTB) the focus of Special Edition of the International Journal of Tuberculosis and Lung Disease (IJTLD)
Drug-resistant TB (DRTB) continues to be a public health threat and is one of the leading antimicrobial resistant infections globally. Worldwide in 2019, close to half a million people developed DRTB. However, only 38 per cent of people with DRTB started treatments and of those treated, only 57 per cent were treated successfully.
World Lung Cancer Day 2020: Respiratory groups stress lung cancer risks and importance of early screening and treatment
In support of World Lung Cancer Day, the Forum of International Respiratory Societies calls for more awareness and understanding of lung cancer risk factors, as well as the importance of early screening and treatment.
The Union congratulates India’s Ministry of Health and Family Welfare for adopting measure to prevent tobacco industry interference in health policy
The Code of Conduct, effective from 6 July 2020, restricts officials and staff from collaborating with the tobacco industry.